Frugi Biotechnology
BigHat Biosciences is a Series B biotech company based outside San Francisco, focused on designing safer and more effective antibody therapies using machine learning and synthetic biology. Their Milliner platform integrates a high-speed wet lab with advanced machine learning technologies for antibody discovery and engineering. With over $100 million raised from top investors, BigHat is developing a pipeline of therapeutic programs aimed at addressing challenging diseases, positioning itself as a leader in the biotech industry.
Frugi Biotechnology
BigHat Biosciences is a Series B biotech company based outside San Francisco, focused on designing safer and more effective antibody therapies using machine learning and synthetic biology. Their Milliner platform integrates a high-speed wet lab with advanced machine learning technologies for antibody discovery and engineering. With over $100 million raised from top investors, BigHat is developing a pipeline of therapeutic programs aimed at addressing challenging diseases, positioning itself as a leader in the biotech industry.
TL;DR
Founded: 2020
Headquarters: Ames, Iowa, United States
Core product: Modular, paper-based diagnostics for viral outbreak management
Acquisition: Acquired by BigHat Biosciences (announced Mar 28, 2022)
Notable funding: NSF grant announced Aug 1, 2021
Company Overview
Problem Domain
Viral outbreak detection and diagnostics
Founded
2020
Industry
Biotechnology; Diagnostics
Funding Track Record
Grant announced Aug 1, 2021; amount obfuscated in source
Acquired by BigHat Biosciences; announced Mar 28, 2022